Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Haemonetics Corporation HAE

Healthcare — Medical Devices
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.10
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — 1 — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
1.59%

Capital & Financial Ratios

Market Cap
4,900.00
Revenue
1,352.01
Net Income
96.29
Free Cash Flow
292.53
Net Debt
950.77
Current Ratio
3.08
Debt/Equity
1.40
P/E ratio
51.80
P/S ratio
3.56
P/B ratio
5.75
Past 5Y EPS Growth
17.48%
This Y EPS Growth
7.03%
Next Y EPS Growth
8.81%
Next 5Y EPS Growth
9.34%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2029 ‡‡‡
2028 ‡‡‡
2027 ‡‡‡
2026 ‡‡‡
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2024 2025 2026 Q'26
Cash 178.80 306.76 245.44 223.38
Receivables 206.56 202.66 216.86 216.07
Inventory 317.20 365.14 306.37 306.74
Other 66.34 60.41 66.21 64.64
768.90 934.98 834.88 810.83
2024 2025 2026 Q'26
Payables 73.36 67.00 51.06 56.34
ST’ Debt 10.23 303.56 5.02 4.96
Other 136.09 148.13 158.34 163.80
300.38 578.11 282.60 263.24
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Jun Sep Dec Mar Year
’26 339.38 — — —
—
’26 321.39 327.32 338.97 346.35
1,334.03
’25 336.17 345.51 348.54 330.60
1,360.82
’24 311.33 318.18 336.25 343.29
1,309.06
’23 261.46 297.49 305.30 304.42
1,168.66
’22 228.53 239.90 259.77 265.00
993.20
’21 195.58 209.49 240.37 225.03
870.46
in millions of $

Operating Cash Flow

Jun Sep Dec Mar Year
’26 52.32 — — —
—
’26 17.40 111.32 93.56 70.94
293.22
’25 (27.42) 48.82 43.77 116.56
181.73
’24 19.09 99.12 (0.54) 64.08
181.75
’23 41.99 87.04 64.42 79.61
273.06
’22 (1.68) 43.46 62.43 68.05
172.26
’21 11.81 29.16 66.29 1.55
108.81
in millions of $

Free Cash Flow

Jun Sep Dec Mar Year
’26 44.65 — — —
—
’26 13.94 106.43 87.65 53.81
261.82
’25 (16.93) 39.58 35.47 103.37
165.70
’24 11.81 90.53 (14.85) 57.95
145.44
’23 (2.98) 58.12 47.73 (19.53)
83.34
’22 (15.03) 22.94 36.33 33.54
77.78
’21 4.52 21.31 57.10 (9.35)
73.58
in millions of $

EPS

Jun Sep Dec Mar Year
’26 0.72 — — —
—
’26 0.70 0.81 0.95 (0.44)
2.05
’25 0.74 0.66 0.74 1.17
3.31
’24 0.80 0.48 0.61 0.40
2.29
’23 0.38 0.64 0.64 0.57
2.24
’22 (0.09) 0.29 0.45 0.19
0.84
’21 0.21 0.94 0.62 (0.22)
1.55

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.7
1
Buy
2
3
Hold
4
5
Sell
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 43.50 72.26 70.25 47.32 51.00 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 86.58 95.26 97.97 87.32 109.57 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,821 3,034 3,657 3,023 3,009 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.35 0.39 0.36 0.45 0.44 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 993.20 1,168.66 1,309.06 1,360.82 1,334.03 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 50.90% 52.63% 52.83% 55.04% 59.04% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 63.63 141.40 151.87 212.07 128.03 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.41% 12.10% 11.60% 15.58% 9.60% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 43.38 115.40 117.56 167.68 97.31 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 101.15 93.31 100.56 130.54 117.53 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 19.46 23.01 25.82 27.04 28.28 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 0.84 2.24 2.32 3.33 2.05 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.37 5.38 3.58 3.61 6.22 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.85) (3.74) (0.72) (0.32) (0.67) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.52 1.64 2.87 3.29 5.55 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.68 16.11 18.93 16.31 16.88 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 51.05 50.78 50.71 50.33 47.18 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 75.26 36.78 37.03 19.03 27.76 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.25 3.60 3.28 2.35 1.99 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.31 5.14 4.48 3.90 3.34 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.77 4.01 3.76 3.03 2.73 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 48.19 56.29 33.89 24.84 13.90 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 172.26 273.06 181.75 181.73 293.22 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (94.49) (189.72) (36.31) (16.02) (31.40) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 77.78 83.34 145.44 165.70 261.82 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 313.77 517.91 468.52 356.86 552.28 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 780.44 773.10 807.79 1,224.79 1,224.58 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 520.95 488.64 628.99 918.03 979.14 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 749.42 818.00 959.96 820.84 796.32 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.36% 6.08% 5.69% 7.22% 4.02% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.97% 7.46% 6.49% 7.97% 5.52% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.86% 14.72% 13.22% 18.83% 12.03% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Haemonetics Corporation (HAE), a steady player in blood management and plasma collection, has delivered reliable revenue growth from $909 million in 2016 to $1.31 billion in 2024 at a 4.7% CAGR, with gross margins expanding to 55% amid cost efficiencies and niche market strength. Despite a sharp COVID-induced dip in 2021, recovery was robust—18% revenue jump in 2023—bolstered by acquisitions like Cardiva Medical and high productivity (over $450,000 revenue per employee). Yet, the stock trades at a steep discount to analyst targets (28-87% upside potential), with compressed multiples (PE 19x, PS 2.4x) signaling undervaluation relative to improving fundamentals.

Profitability has transformed dramatically, flipping from 2016 losses to $118 million net income and $3.33 EPS in 2024, with FCF per share doubling to $3.29 and ROE at 18.8%. Balance sheet equity rose 33% to $960 million, providing buffers like $519 million working capital, though net debt sits at $918 million. Analysts project revenue to $1.49 billion and EPS to $4.76 by 2028 (6-7% CAGR), fueled by plasma demand and buybacks shrinking shares.

While insider confidence shines—a rare director buy with no sells—risks warrant caution: rising debt (up 51% in 2024), potential rate pressures, supply chain geopolitics, and reimbursement hurdles could cap gains. For risk-averse investors eyeing steady medtech performers, HAE’s FCF coverage and historical rebounds offer skewed reward, but monitor debt trends and Q1 2026 earnings closely.

Read full commentary →

Haemonetics Corporation (HAE) Latest News

News by impact score

Fine-tune

15 Sep

3 , 8:30 AM
Haemonetics acquires Vivasure triggering $6.1 million milestone payment to Orchestra BioMed. Vivasure acquisition adds vascular device capabilities to Haemonetics operations.

20 Aug

3 , 10:11 AM
Haemonetics Corporation (HAE) is identified as a Russell 2000 stock with competitive advantages while two others are declined. Highlighting competitive advantages may lift near-term investor sentiment for Haemonetics without altering core operations.

15 Aug

4 , 10:08 PM
Haemonetics raised its guidance, leading to the conclusion that its stock trades at a 49% discount to fair value. Raised guidance signals stronger earnings trajectory and can materially lift investor sentiment and share price.

3 , 9:15 PM
Haemonetics Corporation beat earnings expectations, refocusing attention on its fair value. Earnings beat can moderately influence stock valuation and near-term investor sentiment.

3 , 4:37 AM
Haemonetics Corporation's Q2 earnings call featured five insightful analyst questions on business performance and outlook. Analyst questions during Haemonetics Q2 earnings call highlight areas of investor focus that may influence short-term stock sentiment.

14 Aug

4 , 11:30 AM
Haemonetics Corporation stock rose after Q1 earnings and revenue beat estimates, with fiscal 2027 outlook raised. Q1 earnings beat combined with raised fiscal 2027 guidance signals stronger financial trajectory and lifts investor sentiment for Haemonetics.

13 Aug

3 transcript www.fool.com, 8:01 AM
Haemonetics Corporation held its Q1 2027 earnings call, reporting quarterly financial results and business outlook. Earnings releases and calls deliver key metrics that can shift near-term valuation and sentiment.

11 Aug

3 , 9:15 AM
Haemonetics relies heavily on international sales, creating exposure to currency risks, regional demand shifts, and global trade factors that investors must weigh for the company's outlook. International sales exposure can moderately sway Haemonetics financial results through currency and regional market variables without fundamentally reshaping strategy.

9 Aug

3 , 11:49 PM
Haemonetics Q2 results show plasma and interventional segment growth driving outperformance with steady margin outlook. Q2 outperformance in core segments improves near-term financial results and sentiment without altering long-term trajectory.

8 Aug

3 transcript www.marketbeat.com, 7:03 AM
Haemonetics Q1 revenue rose 8% year-over-year to $312 million, adjusted EPS reached $1.12, both blood center and hospital segments grew, and full-year guidance was raised. Quarterly results and raised guidance supply fresh financial data that can shift near-term sentiment and valuation multiples.

6 Aug

4 transcript , 3:06 PM
Haemonetics posted strong Q1 2027 results that prompted the company to raise its full-year guidance. Raised guidance after a strong quarter signals materially better expected revenue and earnings trajectory.

3 transcript app.moby.co, 6:46 PM
Haemonetics Corporation held its Q1 2027 earnings call, reporting financial results, operational metrics, and forward guidance. Quarterly earnings and guidance directly inform near-term financial expectations and investor positioning.

3 , 6:18 AM
Haemonetics Corporation beat Q2 CY2026 sales expectations. Sales beat against expectations signals moderately stronger revenue growth for Haemonetics.

4 Aug

3 , 4:10 PM
Haemonetics shares rose 5.1% after release of new real-world study data on VASCADE MVP XL, prompting questions on whether the bull case has changed. New VASCADE MVP XL real-world study data triggered a 5.1% stock gain with moderate but not transformative effects on market positioning.

3 Aug

3 , 4:15 PM
Haemonetics' VASCADE MVP XL System shows effectiveness in electrophysiology procedures with large bore sheaths per new study results. Positive study data on VASCADE MVP XL may support greater product adoption and modestly strengthen Haemonetics' position in electrophysiology.

30 Jul

3 , 10:00 AM
Haemonetics (HAE) Q1 earnings are projected to decline from prior-year levels. Anticipated Q1 earnings decline may exert moderate pressure on near-term stock performance and investor sentiment.

25 May

3 , 9:14 AM
Haemonetics (HAE) shares rose 14.3% after the company beat earnings estimates and received an upgrade from BofA, with discussion of subsequent outlook. Earnings beat and BofA upgrade deliver short-term positive momentum without signaling transformative changes to long-term trajectory.

22 May

3 StockStory, 9:48 PM
Haemonetics (NYSE:HAE) posted Q1 results that placed it among notable performers in the medical devices and supplies specialty sector. Q1 performance data can moderately affect near-term investor views on operations and positioning.

3 Zacks, 9:15 AM
Investors considering Haemonetics Corporation shares must review the firm's international revenue trends to gauge growth prospects and risks outside domestic markets. International revenue trends can moderately shift perceptions of Haemonetics' growth trajectory and valuation.

11 May

4 Zacks, 2:24 PM
Haemonetics Corporation (HAE) stock rose after Q4 earnings and revenue exceeded expectations, despite a reduction in gross margins. Q4 earnings and revenue beats signal strong financial performance and boost investor sentiment, outweighing gross margin cut.

10 May

4 www.marketbeat.com, 3:04 PM
Haemonetics Corporation's Q4 earnings call highlighted financial results, strategic updates, and future outlook. Q4 earnings call highlights cover financial performance and guidance that significantly influence Haemonetics' trajectory and investor sentiment.

8 May

4 transcript www.fool.com, 11:40 AM
Haemonetics (HAE) Q4 2026 earnings call transcript released, detailing financial results, management discussion, and future outlook. Q4 earnings transcripts reveal annual financial performance, strategic updates, and guidance, significantly impacting investor sentiment and stock trajectory.

4 app.moby.co, 8:30 AM
Haemonetics Corporation released Q4 2026 earnings call summary, detailing financial results, revenue growth, profitability metrics, and forward guidance for fiscal 2027. Q4 earnings summaries disclose critical financial outcomes and guidance that significantly sway investor confidence and stock trajectory.

7 May

4 Zacks, 9:30 AM
Haemonetics Corporation (HAE) reported Q4 earnings, analyzing key metrics for performance insights. Q4 earnings reports critically shape financial outlook, guidance, and investor confidence, driving substantial market reactions.

4 StockStory, 6:16 AM
Haemonetics (NYSE:HAE) reported upbeat Q1 CY2026 results. Upbeat quarterly earnings signal strong financial health capable of significantly enhancing stock performance and long-term investor sentiment.

3 Zacks, 7:10 AM
Haemonetics Corporation (HAE) reported Q4 earnings and revenues that surpassed analyst estimates. Q4 earnings and revenues beating estimates positively influences financial performance and investor sentiment without fundamentally altering long-term trajectory.

28 Apr

4 Simply Wall St., 1:05 PM
Haemonetics (HAE) could see a shift in its electrophysiology growth narrative from expanded FDA labeling for VASCADE MVP XL, enhancing its vascular closure device for larger sheaths and potentially boosting adoption in electrophysiology procedures. Expanded FDA labeling for VASCADE MVP XL enables use with larger sheaths, positioning Haemonetics for significant growth in the electrophysiology market.

24 Apr

3 PR Newswire, 6:20 AM
New study demonstrates safety and efficacy of Haemonetics' VASCADE MVP® XL for large-bore venous access closure procedures. Positive clinical data on VASCADE MVP XL bolsters product credibility and may drive adoption in vascular closure procedures.

30 Mar

4 PR Newswire, 4:15 PM
Haemonetics Corporation received FDA approval for expanded labeling of the VASCADE MVP® XL Venous Vascular Closure System, enabling use across a broader range of sheath sizes for venous procedures. FDA approval expands indications for the VASCADE MVP XL system, boosting market potential and revenue in vascular closure.

15 Mar

4 Simply Wall St., 6:07 AM
Haemonetics experiences hospital demand rebound and NexSys expansion, potentially reframing its competitive positioning. Hospital rebound and NexSys expansion represent major strategic developments boosting operations and competitive edge.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us